Endpoints 100 1H 2026 CEO survey: optimism rebounds on hot M&A and IPOs; 64% see MFN delaying ex-US filings as execs demand a stable, faster FDA.
This time a year ago, biotech execs were in the worst mood we’ve seen in the eight years we’ve been surveying them. IPOs were on …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
Big obesity bets and China's rise fuel potential $2T in 2032 drug sales: Evaluate
‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs
Pharmalittle: We're reading about an FDA commissioner candidate, Germany's plans for drug prices, and more
At BIO, tension over China biotech deal regulation looms
We hope 2026 is calmer after tariffs, public health chaos, and the cancellation of billions of research funding and health…
There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a…
Executives seek “skin in the game” despite signs of a stock market cooldown.
When President Donald Trump rolled out his plan to levy a 100% tariff rate on patented pharmaceutical products and ingredients…
The FDA's new path, the status of animal testing, and other biotech news from The Readout
FDA's top gene therapy regulator steps down, Trump's plan to lower GLP-1 prices, and more biotech news
